Janssen seeks FDA approval of amivantamab for EGFR mutation-positive NSCLC
Janssen’s BLA for amivantamab marks the first regulatory submission for the treatment of EGFR exon 20 insertion mutation-positive…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
04 Dec 20
Janssen’s BLA for amivantamab marks the first regulatory submission for the treatment of EGFR exon 20 insertion mutation-positive…
04 Dec 20
Orladeyo is the first once-daily oral therapy specifically designed to prevent attacks of HAE patients, by decreasing the…
03 Dec 20
The UK regulator MHRA has authorised the supply of mRNA-based Covid-19 vaccine for emergency use, with US FDA…
03 Dec 20
Gavreto is indicated for metastatic RET-mutant medullary thyroid cancer (MTC) in adult and paediatric patients, aged 12 years…
01 Dec 20
Forxiga is claimed to be the first approved SGLT2 inhibitor for chronic heart failure with reduced ejection fraction…
01 Dec 20
Dupixent is a fully-human monoclonal antibody discovered using Regeneron's original VelocImmune technology
The Japanese regulatory approval of cabometyx is based on results from two clinical trials: Phase 3 CELESTIAL and…
26 Nov 20
Janssen claimed that its Tremfya is the first selective IL-23 p19 subunit inhibitor licensed for both the treatment…
26 Nov 20
FDA indicated danyelza in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of neuroblastoma
25 Nov 20
The EC approval is based on Phase 3 ATTRACTION-3 trial, which showed positive results for Opdivo in improving…